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1. Introduction 
Polymerase chain reaction (PCR) invented by Karry Mullis in 1983 is a cornerstone of 
molecular biology techniques. Polymerase chain reaction (PCR) is used to generate millions 
of copies of a DNA sequence in a short interval. PCR is commonly used for a variety of 
applications including diagnosis of genetic disease, cloning, QTLR analysis, forensic 
analysis, diagnosis of infectious diseases. Polymerase chain reaction becomes indispensable 
technique in medical sciences these days for the diagnosis of infectious diseases. Molecular 
genetic testing has made possible to identify the mutations in first degree relatives of index 
case even in the absence of clinical and biochemical presentations of symptoms. PCR is a 
basic step in molecular genetic testing. 
 Wilson disease is a genetic disorder of copper metabolism with hepatic or neuropsychiatric 
presentations [1]. The copper-transporting P-type ATPase, ATP7B gene was identified in 
1993 (ATP7B; OMIM 606882) [2] and found responsible for WND. Copper is a nutritional 
trace element and play indispensable role in variety of biological reactions [3, 4]. The 
homeostasis of copper is maintained by liver. It regulates excretion of copper into bile and 
into secretary pathway. Ceruloplasmin protein is abundant in blood and plays functional 
role in copper transport. Copper excretes from hepatocytes as ceruloplasmin or through bile 
[5, 6]. The human Cu-ATPases regulate the intracellular copper homeostasis. The copper is 
transported from cytosol to secretory pathway using energy released by the hydrolysis of 
ATP and supply the copper for various copper-dependent biological process and enzymes. 
The biosynthesis of copper-dependent ferroxidase ceruloplasmin is dependent on ATP7B. In 
addition, Cu-ATPases play part in export of excess copper out of the cell [7, 8, 9]. 
Liver is involved in the copper homeostasis and remove excess copper via bile [10] through 
the activity of ATP7B transporter. Therefore defect in ATP7B gene results in disturbance of 
copper homeostasis and caused WND [2, 11] due the copper accumulation in liver, brain 
and cornea.  
ATP7B is present in the Golgi & trans-Golgi Network (TGN), travel to the vesicular 
compartment. There, ATP7B delivers copper to ceruloplasmin in the cell which is copper 
binding protein [12, 13]. ATP7B gene contains six copper binding domains, transduction 
domain, cation and phosphorylation domain, nucleotide-binding domain and eight 
hydrophobic transmembrane sequences [7]. The Wilson disease gene ATP7B was localized 
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at chromosome 13 on q14.3 band and cloned in 1993. ATP7B gene comprised of 21 exons 
which encodes 1465 amino acid residues [2, 14, 15].  
The WND diagnosis is complex due to variable disease onset and clinical symptoms. 
Clinical symptoms of the disease include hepatic, neurologic and psychiatric disturbances 
[16]. WND patients with hepatic manifestation may present asymptomatic to mild 
hepatomegaly, cirrhosis, acute hepatitis and jaundice. Haemolysis can be present in acute 
liver failure [17, 18, 19]. 
Neurological symptoms mostly appeared in second decade of life due to the toxic copper 
accumulation in brain that damages the nerve cells. This leads to hypokinetic speech, 
tremor, dystonia and later dysphagia, mutism and Parkinsonism. Hepatic and neurological 
presentations in combination have been observed in 50% WND patients [20, 21].  
Psychiatric symptoms have been seen in the early stages of WND including incompatible 
behavior, irritability, depression and cognitive impairment [22, 23].   
Therefore, molecular testing of WND [21, 24] has served as a very useful approach for 
presymptomatic disease diagnosis in the absence of clinical symptoms. In present study, we 
investigated presymptomatic WND in siblings of two index case of Wilson disease. 
2. Material and methods 
The informed consent was obtained from all subjects and study was approved from ethnic 
committee of the institution.  
2.1 Subjects 
Two families with WND patients were enrolled for present study. The age of patients was 
between 7-11 years and of siblings was between 2-5 years. The children of family 1 were 
born to non-consanguineous parents. History of patient belongs to family I was described 
earlier [25]. The children of family II were born to consanguineous parents. Past family 
history was negative for presence of WND. However, liver disease was reported in family II.  
Patients were enrolled for mutational analysis based on clinical diagnosis. Siblings were 
screened for presymptomatic WND. The patients of family II were 11 & 8 years old. The 
laboratory investigations of respective patients were described in table 1 & 2. The siblings of 
index patients were included without clinical data. Patients of this family were presented 
with hepatic manifestation. The 11 year old boy was also patient of hepatitis C. 
2.2 Mutational analysis 
DNA was extracted from peripheral blood of all subjects by standard phenol/chloroform 
extraction method [26]. The quality plus quantity of DNA was checked through gel 
electrophoresis and spectrophotometer. PCR was done in 30μl volume containing 200ng 
genomic DNA, 1X Taq buffer, 200μM dNTPs mixture, 2.5 pmol of both primers, 1unit of Taq 
polymerase. The PCR conditions were optimized for 11 exons of ATP7B gene. The PCR 
products were purified through PCR purification kit (Genomed GmbH Inc). For sequencing, 
0.1-0.5ng of PCR product was used as template and sequencing PCR was performed with 
quickstart DTCS kit (Beckman Coulter). The sequencing PCR program was comprised of 30 
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cycles: 96◦C for 20 seconds, 20 seconds at respective annealing temperature and 60◦C for 4 
min. Salt precipitation method was used to remove unincorporated dye terminators as 
described by manufacturer.  The sequencing was performed with forward and reverse 
primers on CEQ8000 Genetic Analyzer (Beckman Coulter). The sequences were compared 
for the detection of mutation through BioEdit Sequence Alignment Editor ver 7.0.9.0.  
3. Results and discussion 
Wilson disease is a recessive autosomal disorder caused by increased accumulation of 
copper in liver, brain, cornea [5]. The prevalence of WND is around 1:30,000 with carrier 
frequency 1:90 [27] while 4% carrier frequency is also reported [28]. Clinical presentation of 
disease is variable and mostly appears between ages 5 to 35 with rare case of onset in 2 to 72 
years [29, 30]. The diagnosis of WND is based on presence of KF ring, low plasma 
ceruloplasmin, elevated urinary copper and liver copper concentration [1, 24].  WND is 
caused due to defect in ATP7B gene, which is copper transporter. The worldwide data 
revealed the population specific pattern of ATP7B gene mutations. The most common 
mutation found in Europe, American and Greece population was H1069Q in exon 14.  
About 50–80% of WND patients from these countries carry at least one allele with this 
mutation with an allele frequency ranging between 30 and 70% [28, 31, 32]. Mutational 
analysis of ATP7B gene has been extensively carried out in Chinese population and showed 
a high prevalence of WND. Mutations have been detected in all exons except 21. Most 
mutations were found in exons 8, 12, 13 and 16 accounts for 74.0% of the reported WND 
alleles. The most frequent WND mutations were p.Arg778Leu and p.Pro992Leu, which 
account for 50.43% of all the reported WND alleles in Chinese population [33, 34]. The 
R778L mutation was also frequent in Korean and Taiwan population with an allele 
frequency of 20-35% & 55.4% [35, 36, 37]. In addition to R778L mutation at exon 8, hotspot 
for ATP7B mutation in exon 12 were also detected in Taiwan WND patients [38] where 
9.62% of all mutations occurred.  
The spectrum of ATP7B gene mutations in our population is yet to be studied. In present 
study, the siblings of index patients of WND were screened for mutations in ATP7B gene. 
We enrolled two families for genetic testing and novel mutation was described previously in 
one patient [25]. The past history of patients revealed the sudden onset of disease while no 
WND patient was reported earlier in these families. Based on current family history, siblings 
were screened for presympotomatic WND. The exon 15 and 19 were amplified at 55°C. The 
exons 16, 17, & 21 were optimized at 64°C. Same annealing temperatures were used for 
sequencing PCR. Phenotypic data of subjects of family 1 was found normal. No laboratory 
investigations were performed at the time of genetic testing. The family members of patient 
were screened without relying on clinical data. The patients and siblings were born to non-
consanguineous parents. The parents were also found normal in genetic testing.  
The family-II was also presented with same history. The family did not have any past WND 
history. The two child of respective family were declared WND patient. The phenotypic 
presentations of sibling and parents were found normal. However, occurrence of liver 
diseases (details not available) was reported in three generations. The parents were not 
reported any type of liver disease. The Hb level of sibling was reported below normal range 
when he was 3years old. We encountered problem in collecting blood sample from family-
II. Therefore we reamplified each exon through PCR with same product to get product in 
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sufficient quantity. This step reduced the chance for loss of sample. Because subjects were 
belonged to remote area and access to them was not feasible. 
 
Fig. 1. PCR amplification of samples of family 1 
a) Exon-15, b)Exon-16, c)Exon-17, d)Exon-19, e)Exon-21  
 
Patients CP U-Cu          ALT 
Normal <20mg/dl >100mg/24h 7-45 U/L 
8a 6.8 mg/dl 1796mg/24h 40 U/L 
8f 20 mg/dl 1000mg/24h 200 U/L 
Table 1. Biochemical analysis of WND patients of family II 
 
Patients     Hb Total  
Bilirubin 
 AST ALP Serum 
Albumin 
Normal 13-17 g/dl 0.3-1.2 mg/dl 7-45U/L 98-279 U/L 3.5-5.5 g/dl 
8a 8.9 g/dl 1.8 mg/dl 1400 U/L 569 U/L 2.3 g/dl 
8f 5 g/dl 30 mg/dl 450 U/L 350 U/L 2.2 g/dl 
Table 2. Clinical features of WND patients of family II 
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Fig. 2. PCR amplification of samples of family II  
a) Exon-15, b)Exon-16, c)Exon-17, d)Exon-19, e)Exon-21 
 
Fig. 3.  Sequencing of ATP7B gene  
a) Family 1, b) Family II 
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The phenotypic presentations of sibling were found normal. Fig 1 & Fig 2 shows the PCR 
amplification of respective exons. In mutational analysis, subjects of both families were 
detected negative for any mutation on exons 15, 16, 17, 19 & 21 (Fig 3).  
The prospective of our study was the screening of carrier in respective families and 
inclusion of genetic testing for earlier diagnosis of WND. PCR and gene sequencing are the 
basic steps of genetic testing. We have not found prevalent mutation in our Wilson disease 
patients. Screening the siblings is a grueling task when common mutation was not 
identified. Genotyping of ATP7B gene in families of WND patients was first time carried out 
in our country. Genetic testing is useful tool for the screening of presymptomatic WND case 
or carriers in the family of index patient. It could help in genetic counseling of respective 
family based on molecular diagnosis. We have also found that optimization of parameters 
for PCR and sequencing is indispensible for effective screening. The result’s integrity 
dependent on quantity and quality of template and is a paramount factors in PCR. 
Presymptomatic diagnosis through genetic analysis could help to stop progression & 
prevention of the disease and timely treatment. The Taqman allelic discrimination reported 
a valid technique for efficient screening of common mutation in index patient and sibs [39]. 
Single nucleotide polymorphism (SNP) have also been studied in combination with the 
prevalent mutations for WND diagnosis and evaluated as a comprehensive strategy for the 
detection presymptomatic or carrier sibs of WND patients [40].  
4. Conclusion  
This case has provided a base to establish a system for genetic testing for the earlier 
diagnosis of disease and detection of heterozygote carrier. PCR based genetic testing using 
different approaches like multiplex PCR, SNP markers and Taqman assay will turn into a 
cost effective screening. These results further more have provided a platform for haplotype 
analysis. Presymptomatic diagnosed patient can undergo regular treatment to prevent 
disease progression and onset.  
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